|
PNMA1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62458935193399E-12 |
| Normal-vs-Stage2 |
3.71380000000476E-05 |
| Normal-vs-Stage3 |
8.8845997225917E-10 |
| Normal-vs-Stage4 |
9.51390000114571E-08 |
| Stage1-vs-Stage2 |
6.361600E-01 |
| Stage1-vs-Stage3 |
4.614800E-01 |
| Stage1-vs-Stage4 |
7.133200E-01 |
| Stage2-vs-Stage3 |
3.861600E-01 |
| Stage2-vs-Stage4 |
5.169800E-01 |
| Stage3-vs-Stage4 |
8.009000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
2.238500E-04 |
| Normal-vs-Asian |
1.40279999838455E-08 |
| Caucasian-vs-AfricanAmerican |
2.488600E-01 |
| Caucasian-vs-Asian |
6.769900E-02 |
| AfricanAmerican-vs-Asian |
8.653800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.91160000553958E-08 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
1.332170E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.64224189802553E-12 |
| Normal-vs-Age(41-60Yrs) |
1.4432899320127E-15 |
| Normal-vs-Age(61-80Yrs) |
1.53959999971143E-07 |
| Normal-vs-Age(81-100Yrs) |
2.560300E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.222800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.177150E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.200200E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.176100E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.623970E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.902820E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.060820E-01 |
| Classical-VS-Follicular |
1.60477999999742E-05 |
| Classical-VS-Other |
1.679800E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
9.561800E-02 |
| Tall-VS-Other |
5.264000E-01 |
| Tall-VS-Normal |
3.49659999998586E-06 |
| Follicular-VS-Other |
9.511800E-01 |
| Follicular-VS-Normal |
1.044780E-03 |
| Other-VS-Normal |
3.576600E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.39681665812486E-12 |
| Normal-vs-N1 |
1.774720E-04 |
| N0-vs-N1 |
5.809200E-01 |
|
|
